NEW YORK (GenomeWeb) – Precipio is out of compliance with a Nasdaq listing requirement, the firm said in a document filed Friday with the US Securities and Exchange Commission.

The company said Nasdaq notified it on March 26 that for the past 30 consecutive business days, the closing bid price per share of its common stock was below the $1 minimum needed for continued listing.

Nasdaq has given Precipio a grace period until Sept. 24, 2018 to regain compliance by ensuring that its common stock price meets or exceeds $1 per share for at least 10 consecutive business days.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Reuters reports that UK researchers are using gene-editing tools to develop flu-resistant chickens.

Nature calls for genomics to become part of the World Health Organization's cholera surveillance approach.

Vox explores a proposal to institute a lottery system to award grant funds.

In Genome Biology this week: gut microbiome study of individuals from Tanzania and Botswana, sixth version of the Network of Cancer Genes database, and more.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Feb
21
Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Mar
13
Sponsored by
Horizon Discovery

This webinar will discuss development and validation of an assay for detection of microsatellite instability (MSI) based on a novel set of biomarkers.